Our partnerships

To create a step change in pancreatic cancer research, treatment and survival, we build partnerships to share best practice and demand better outcomes for people with pancreatic cancer. We also work hard to bring pancreatic cancer to the forefront in terms of campaigning and awareness.

Collaborating for success

We need to ensure that pancreatic cancer remains a priority on the political agenda in the UK. To help achieve this we provide the secretariat to the All-Party Parliamentary Group on pancreatic cancer, a group of parliamentarians with an interest in making a difference for pancreatic cancer. The APPG has run a number of inquiries in particular looking at the need for greater research investment and earlier diagnosis.

We are also founding members of the  Less Survivable Cancers Taskforce and the Taskforce is Chaired by Anna Jewell our Director of Support, Research & Influencing. The Taskforce represents the six common cancers of lung, liver, brain, oesophageal, pancreatic and stomach, which all with a five-year survival rate of less than 30% due to a legacy of neglect and underfunding. We are calling for prioritisation of these cancers by Governments across the UK and want to see the survival rate for these cancers to double to 28% by 2029.  In 2019/20, our work with the led to the cancer sector’s One Cancer Voice UK and Wales manifestos focusing on tough cancers, including pancreatic cancer.

We know that by working together we can change the future for those affected by pancreatic cancer. We believe that collaborating with global charitable organisations will also enable us to make faster progress on pancreatic cancer, by sharing of knowledge and expertise.  We sit on the steering committees for the World Pancreatic Cancer Coalition, and World Pancreatic Cancer Day and work together to raise awareness and highlight the need for more funding and research.

We work alongside the other UK pancreatic cancer charities on these initiatives and have regular meetings with Pancreatic Cancer Action and Pancreatic Cancer Research Fund.

Collaboration in research is also essential to drive faster progress. In 2020, we joined the National Cancer Research Institute, enabling us to influence policy and collaborate on research initiatives alongside other leading UK cancer charities, funders and NHS England.

Supporting others to achieve their aims

The Living with and beyond pancreatic cancer Facebook group predominantly support one another via the group or even sometimes via telephone, but twice a year we fund meet-ups in person as well as making sure our Pancreatic Cancer UK specialist nurses are on hand to answer any questions attendees might have.

Whilst current restrictions are preventing the group from meeting in person, we’re helping facilitate the group meeting online to support one another, with input from one of our nurses.

Find out more about this group

Working with pharmaceutical industry

We recognise the importance of working collaboratively with all stakeholders with an interest in pancreatic cancer. Working with pharmaceutical companies and medical device companies gives us important background knowledge and expertise whilst also enabling us to achieve the charity’s mission. It can also help ensure that stakeholders have a shared understanding of the needs of people affected by pancreatic cancer.

Find out more about how we work with the Pharmaceutical industry

  • Demanding Survival at Downing Street

    Demanding Survival at Downing Street

    Last week we handed in our open letter, signed by over 63,000 Pancreatic Cancer UK supporters who backed our Demand Survival Now manifesto.

  • A day in the life working on the support line

    A day in the life working on the support line

    Nicci is one of our specialist nurses. This is an example of a day in the life working on the support line.

  • Our response to the PERT shortages

    Our response to the PERT shortages

    Find out more about the PERT shortages, what we're doing in response and how we can support you if you're affected.